Bausch + Lomb enters its third-quarter report with something it has not always had: credibility. Management has now strung together several quarters of doing what it said it would do, raising its full-year outlook twice and delivering an 8% constant-currency growth rate last quarter alongside a sharp margin expansion. The question for October 28 is whether that momentum holds as the calendar turns against it, with the second half of 2026 lapping a strong stretch from a year earlier.

Wall Street is looking for earnings of $0.21 per share on revenue of about $1.37 billion. That implies roughly 7% top-line growth and about 17% earnings growth from the year-ago $0.18, solid but not heroic. Notably, the revenue estimate sits slightly below the $1.39 billion the company booked last quarter, which suggests analysts are already building in some caution around tougher comparisons. For the full year, consensus of $5.47 billion lands in the lower half of management's reaffirmed $5.44 billion to $5.54 billion range. That gap matters. If management is confident enough to keep the range intact and the Street is still leaning toward the bottom, a clean quarter could pull estimates higher, while any hint of the low end becoming the target would undercut the recent raise.

Surgical is the swing factor. After growing just 1% in the first quarter while the company rebuilt its U.S. sales force and dealt with weather and reimbursement headwinds, the segment jumped 16% in constant currency last quarter, powered by premium intraocular lenses that grew 175%. Premium lenses reached 13% of surgical revenue, up from 9% in 2025. That is a high-margin mix shift, and it helps explain why adjusted EBITDA margin climbed to 17.6%. Validation this quarter would look like surgical growth that stays comfortably in double digits and a premium mix that keeps inching up. A slide back toward mid-single digits would raise the uncomfortable possibility that the second quarter was a catch-up period rather than a new run rate, especially with Alcon's competing premium lens now in the market.

Pharma offers a second test. Miebo grew 44% to $91 million, and Medicare coverage expanded to 88% from 71% after Humana came on board. That broader access should show up as continued sequential script gains, not just a one-quarter bump. Xiidra, by contrast, is normalizing as it laps the exit from a CVS contract, and growth already slowed to 6%. Investors should expect modest Xiidra numbers; the concern would be outright weakness, particularly with Tryptyr competing in dry eye. On the consumer side, VisionCare grew a steadier 4%, but management flagged sensitivity to gas prices and soft China contact lens growth of just 3%, so a stall there could offset surgical strength.

Cash conversion deserves equal attention. Adjusted operating cash flow tripled to $161 million last quarter and net leverage fell to about 4.7 times. For a company still carrying meaningful debt, another quarter of strong cash generation would confirm that margin gains are real rather than accounting optics. Updates on the Elios glaucoma laser filing and second-half dry eye and ocular pain data readouts could add color, though they are unlikely to move near-term numbers.

The market remains unconvinced. Shares are up 2.8% since the last report, trailing the S&P 500 slightly, and at $16.61 the stock sits right on its 200-day moving average, roughly midway in its post-earnings range. Sentiment has improved from distinctly bearish to essentially neutral, but that is a far cry from enthusiasm, and the Bausch Health ownership overhang still caps interest. Ultimately, this report hinges on whether surgical and Miebo can carry growth through harder comparisons. If they do and the full-year range holds or edges higher, the say-do story earns another chapter. If not, the recent raises may start to look like peaks.